Gillian Jalimnson
Gillian Jalimnson is one of Hemp Gazette's staff writers and has been with us since we kicked off in 2015. Gillian sees massive potential for cannabis in areas of health, energy, building and personal care products and is intrigued by the potential for cannabidiol (CBD) as an alternative to conventional treatments. You can contact Gillian here.
New Cannabis Research Insights from Drug and Alcohol Depend…
CBD Insomnia Trial: Avecho Exceeds Patient Target for Phase…
Cannabinoid Clinical Trials See Significant Growth for New…
Cannabidiol Fragile X Syndrome Trial Fails Primary Endpoint
Cannabinoid Clinical Trials Gain Momentum: 50+ Companies Le…
Cannabidiol Fragile X Trial Fails to Meet Primary Endpoint
CBD Use and Liver Enzymes: New Clinical Trial Highlights Sa…
CBD and Hydroxychloroquine Combination Shows Promise in Pha…
Clinical Trial Begins for Synthetic CBD Drug Development
CBD for Hypertension: Clinical Trial Shows Blood Pressure R…

